FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

Welcome to the Q2 fiscal-year 2025 ResMed earnings conference call. My name is Matt and I'll be your operator for today's call. (Operator Instructions) Please note that this conference call is being ...

Shares of ResMed (NYSE:RMD) fell 6% today, despite the company reporting second-quarter earnings that surpassed analyst ...

Q2 2025 Earnings Call Transcript January 30, 2025 ResMed Inc. beats earnings expectations. Reported EPS is $2.43, expectations were $2.32. Operator: Welcome to the Q2 Fiscal Year 2025 ResMed Earnings ...

For pediatric insomnia, Dr Umakanth Katwa and Dr Rafael Pelayo call for a blend of clinical expertise, behavioral therapy, and empathy.

Axsome Therapeutics, Inc. , a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, will host a virtual investor event and conference call today at ...

Chronic obstructive pulmonary disease (COPD) is a manifestation of structural violence, the process through which societies ...